The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Tislelizumab versus chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma (ESCC, RATIONALE 302): Impact on health-related quality of life (HRQoL).
 
Eric Van Cutsem
Consulting or Advisory Role - Array BioPharma; Astellas Pharma; AstraZeneca; Bayer; Biocartis; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; GlaxoSmithKline; Halozyme; Incyte; Lilly; Merck KGaA; Merck Sharp & Dohme; Novartis; Pierre Fabre; Roche; SERVIER; Sirtex Medical; Taiho Pharmaceutical
Research Funding - amgen (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Ipsen (Inst); Lilly (Inst); Merck (Inst); Merck KGaA (Inst); Novartis (Inst); Roche (Inst); SERVIER (Inst)
 
Ken Kato
Honoraria - BMS; Lilly; Ono Pharmaceutical
Consulting or Advisory Role - Bayer; BeiGene; MSD; Oncolys BioPharma; Ono Pharmaceutical
Speakers' Bureau - Bristol-Myers Squibb Japan; MSD; Ono Pharmaceutical
Research Funding - AstraZeneca (Inst); Bayer (Inst); Beigene (Inst); Chugai Pharma (Inst); MSD Oncology (Inst); Ono Pharmaceutical (Inst); Shionogi (Inst); Taiho Pharmaceutical (Inst)
 
Jaffer A. Ajani
Honoraria - Acrotech Biopharma; Aduro Biotech; Amgen; Astellas Pharma; AstraZeneca; BeiGene; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; DAVA Pharmaceuticals; Fresenius Kabi; Gilead Sciences; GRAIL; Lilly; Merck; Novartis; oncotherics; SERVIER; zymeworks
Consulting or Advisory Role - American Cancer Society; BeiGene; Bristol-Myers Squibb; Insys Therapeutics; Merck; Vaccinogen
Research Funding - Amgen; Astellas Pharma (Inst); Bristol-Myers Squibb; Daiichi Sankyo; Delta-Fly Pharma; Gilead Sciences; Lilly/ImClone; Merck; Novartis; ProLynx; Roche/Genentech; Taiho Pharmaceutical; Takeda; Zymeworks
Patents, Royalties, Other Intellectual Property - I have research funding from: Genentech, Roche, BMS, Taiho, MedImmune, Merck, Amgen, Lilly
 
Lin Shen
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squib; Daiichi Sankyo; Harbour BioMed; Merck; Mingji biopharmaceutical; MSD; Roche
Speakers' Bureau - Hutchison Whampoa; MSD
Research Funding - Baiji Shenzhou (Beijing) Biotechnology (Inst); Beijing Xiantong Biomedical Technology (Inst); Nanjing Yaojieankang Biotechnology (Inst); QiLu Pharmaceutical (Inst); Zaiding Pharmaceutical (Inst)
 
Tianyu Xia
Employment - BeiGene
Stock and Other Ownership Interests - BeiGene
 
Ningning Ding
Employment - BeiGene
 
Lin Zhan
Employment - BeiGene
Stock and Other Ownership Interests - BeiGene
 
Gisoo Barnes
Employment - BeiGene
Stock and Other Ownership Interests - BeiGene
Travel, Accommodations, Expenses - BeiGene
 
Sung-Bae Kim
Stock and Other Ownership Interests - Genopeaks; NeogeneTC
Consulting or Advisory Role - AstraZeneca Canada; DAEHWA Pharmaceutical; Daiichi Sankyo; ISU ABXIS; Lilly; Novartis
Research Funding - Dongkook; Novartis; Sanofi